TOR1B

Across TCGA pan-cancer cohorts, TOR1B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TOR1B data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TOR1B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TOR1B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where TOR1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.523	0.900	<.001	36	view →
HNSC	DFS	Median	II,III,IV	0.993	0.897	.005	7	view →
PDAC	OS	Median	IV	0.395	0.937	.026	6	view →
CCRCC	OS	Tertile	II,III,IV	0.277	0.972	.024	2	view →
GBM	OS	Tertile	All	0.405	0.619	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TOR1B–LUAD (OS)

Open the LUAD breakdown →